Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 365R |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Renal |
| Current Generation (* indicates number of generations grown in Castrate host) |
8 |
| Average PDX Generation Time (days +/- SEM) | 224 ± 25 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 365R |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | Y |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 365R | ZNRF3 | -0.929 | 1.050 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | NCOR1 | -0.927 | 1.052 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | TP53 | -0.927 | 1.052 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | PRPF8 | -0.927 | 1.052 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | FANCA | -0.938 | 1.044 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | ZFHX3 | -0.938 | 1.044 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | IGF2R | -0.953 | 1.033 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | PTEN | -1.752 | 0.594 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | SUFU | -1.752 | 0.594 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | CDH1 | -0.938 | 1.044 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | PTEN | -14.453 | 8.920e-05 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | AXIN2 | 0.546 | 2.920 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | SPOP | 0.546 | 2.920 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | CDK12 | 0.597 | 3.025 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | KMT2A | 0.585 | 3.000 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | USP28 | 0.585 | 3.000 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | CCND1 | 1.995 | 7.970 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 365R | MYC | 0.579 | 2.988 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 365R |
|---|---|
| Sample Site | Prostate |
| Sample source | Radical prostatectomy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | 9 |
| Primary Gleason Score | 4 |
| Secondary Gleason Score | 5 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | 5 |
| Tumour Grade | pT3aN1 |
| D'Amico Risk Classification | 7 |
| Tumour Volume (in cc) | 8.6 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 365 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 6.3 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 365R |
| Patient Age (binned in 5 year age groups) | 60-64 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 365R | TP53 | 235 | 1.0 | Stop gained | '10/11 | . | 36 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 365R | PRDM2 | 465 | 0.53 | Missense variant | '8/10 | . | 27.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 365R | NR3C1 | 594 | 0.52 | Stop gained | '2/9 | . | 36 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 365R | CACNA1H | 571 | 0.48 | Missense variant | '17/35 | 0.0007575 | 3.993 | Likely benign | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 365R | SDHA | 408 | 0.47 | Missense variant | '2/15 | 0.0004432 | 22.9 | Conflicting interpretations of pathogenicity | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 365R | RYR1 | 703 | 0.4 | Missense variant | '43/106 | 0.0004264 | 22.5 | Conflicting interpretations of pathogenicity | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 365R | ASPM | 609 | 0.39 | Stop gained | '18/28 | 2.04E-05 | 38 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table